Aging
Navigate
Research Paper|Volume 16, Issue 15|pp 11491—11500

Disease progression in Parkinson’s disease patients with mild cognitive impairment: 5-year longitudinal study from the early Parkinson’s disease longitudinal Singapore (PALS) cohort

Xiao Deng1,2, Seyed Ehsan Saffari1,3, Bin Xiao1,2, Samuel Yong Ern Ng1, Nicole Chia1, Xinyi Choi1, Dede Liana Heng1, Zheyu Xu1, Kay-Yaw Tay1, Wing-Lok Au1,2, Eng-King Tan1,2, Louis CS Tan1,2
  • 1National Neuroscience Institute, Singapore, Singapore
  • 2Duke-NUS Medical School, Singapore, Singapore
  • 3Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore
* Joint senior author
Received: October 31, 2023Accepted: March 29, 2024Published: August 12, 2024

Copyright: © 2024 Deng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Aim: To investigate motor, non-motor and cognitive progression in early Parkinson’s disease (PD) patients with Mild Cognitive Impairment (MCI).

Methods: PD patients were recruited within 1 year of diagnosis and were classified into PD-MCI group and PD with normal cognition (PD-NC) group. H&Y staging scale, MDS-UPDRS part III were used to assess disease severity and motor progression. Non-motor symptom scale (NMSS) was used to evaluate the NMS progression. Cognitive progression was assessed from 5 cognitive domains. Annual progression changes in the longitudinal outcomes were examined via linear mixed model with random intercept effect. False discovery rate (FDR) method was performed to control for multiple testing comparison and q-value was calculated. We set the threshold of q-values as 0.1.

Result: A total of 205 PD patients, including 107 PD-MCI and 98 PD-NC patients were assessed prospectively over a 5-year period. PD-MCI patients, compared to PD-NC group, had a significantly higher progression rate in H&Y score (0.11 vs. 0.06, p=0.03, q=0.08), MDS-UPDRS motor score (3.11 vs. 1.90 p<0.001, q=0.06) and postural instability gait difficulty (PIGD) score (0.40 vs. 0.20, p=0.02, q=0.07). PD-MCI group also exhibited significantly faster deterioration in NMSS perceptual domain (PD-MCI vs. PD-NC: 0.38 vs. -0.04, p=0.01, q=0.06) and cognitive visuospatial domain (PD-MCI vs. PD-NC: 0.13 vs. -0.06, p=0.048, q=0.09) after adjustment for confounders and multiple comparisons.

Conclusions: PD-MCI patients had faster decline in motor functions, visuo-perceptual and visuospatial performance. These findings provide a more comprehensive prognosis of PD-MCI, which could be helpful for clinician to manage PD-MCI patients.